Eva Schaefer-Jansen | Investor Relations |
Paul Hudson | Chief Executive Officer |
Bill Sibold | Executive Vice President-Sanofi Genzyme |
Thomas Triomphe | Executive Vice President-Sanofi Pasteur |
Olivier Charmeil | Senior Executive |
Julie Van Ongevalle | Executive Vice President, Consumer Healthcare |
Jean-Baptiste de Chatillon | Chief Financial Officer |
John Reed | Head of R&D. |
Graham Parry | BofA |
Wimal Kapadia | Bernstein |
Peter Verdult | Citi |
Richard Vosser | JPMorgan |
Geoff Porges | SVB Leerink |
Laura Sutcliffe | UBS |
Jean-Jacques Le Fur | Bryan Garnier |
Brian Tsang | Wolfe Research |
Thibault Boutherin | Morgan Stanley |
Luisa Hector | Berenberg |
Seamus Fernandez | Guggenheim Securities |
Keyur Parekh | Goldman Sachs |
Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Investor Call on the Q3 2020 earnings. I would now like to turn the call over to Eva Schaefer-Jansen from Sanofi Investor Relations. Please go ahead, madam.
Thank you, and good morning and good afternoon to everyone on the call.